Belkyra    injection serves as an effective fat-dissolving treatment for addressing the appearance of a double chin, a condition characterized by the accumulation of fat beneath the chin, often exacerbated by aging. This area contains two distinct fat compartments, separated by the platysma muscle, with the upper compartment being the primary focus for lipolysis injections.

 

Mechanism of action 

Approved by the FDA in 2015, Belkyra    is a Canadian medication that utilizes deoxycholic acid, a naturally occurring substance in bile that aids in fat digestion. When injected, Belkyra disrupts fat cell membranes, triggering an inflammatory response that not only reduces fat volume but also stimulates fibroblast activity, enhancing collagen production in the skin.

 

Injection procedure ​

The procedure involves careful preparation, including obtaining consent, marking the injection site, disinfecting the area, and applying anesthetic cream for comfort, followed by the precise injection of deoxycholic acid into the targeted fat region using a fine needle.

​

Aftercare​

Posttreatment care is essential for managing potential inflammation, which may manifest as mild swelling, discomfort, and pain lasting from two days to two weeks following the injection. To ease these symptoms, cold compresses are recommended.

​

Follow up

Patients are typically scheduled for a follow-up appointment four weeks post-treatment to evaluate the results and determine the need for additional sessions, which usually range from three to five, spaced four weeks apart.

​

Complication

Complications may arise, including discomfort, pain, and swelling, as well as bruising. An asymmetrical smile can occur if excessive deoxycholic acid is injected near the nerve, and in rare cases, skin ulceration or difficulty swallowing (dysphasia) may be experienced

​

​